Background: Ide-cel, a BCMA-directed CAR T cell therapy, showed tolerability and
promising efficacy in patients with relapsed and/or refractory multiple myeloma (RRMM) in …

8503 Background: Outcomes are poor in triple-class exposed RRMM patients (pts) who
progress on immunomodulatory agents (IMiDs), proteasome inhibitors (PIs), and CD38 …

Introduction: Idecabtagene vicleucel (ide-cel) was the first FDA approved BCMA targeted
CAR-T cell therapy for the treatment of relapsed/refractory multiple myeloma (RRMM) …

Idecabtagene vicleucel (ide-cel) is a B-cell-maturation antigen (BCMA)-directed chimeric
antigen receptor T cell therapy. We performed a post hoc analysis of a single-arm phase 1 …

PURPOSE Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–
directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple …

Background: Multiple myeloma (MM) occurs most commonly among the older population,
with a median age of 69 years at diagnosis. Advanced age has been shown to negatively …

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, for the treatment
of patients with relapsed and re Page 1 Idecabtagene vicleucel (ide-cel, bb2121), a …

Background Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation
antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity …

In March 2021, the FDA approved idecabtagene vicleucel, a chimeric antigen receptor T-cell
therapy targeting the B-cell maturation antigen (BCMA), for adult patients with …

Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy
targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for …